{"nctId":"NCT02346721","briefTitle":"Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection","startDateStruct":{"date":"2015-02-23","type":"ACTUAL"},"conditions":["Hepatitis C Virus Infection"],"count":111,"armGroups":[{"label":"SOF/VEL","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL"]}],"interventions":[{"name":"SOF/VEL","otherNames":["GS-7977/GS-5816","Epclusa®"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy\n* Was administered placebo to match SOF/VEL in Gilead study GS-US-342-1138\n* HCV RNA ≥ 10\\^4 IU/mL at screening\n* Classification as treatment naive or treatment experienced\n* Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception\n\nKey Exclusion Criteria:\n\n* Current or prior history of clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with treatment, assessment, or compliance with the protocol; individuals currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded.\n* Screening electrocardiogram (ECG) with clinically significant abnormalities\n* Laboratory results outside of acceptable ranges at screening\n* Prior exposure to SOF or other nucleotide analogue HCV NS5B inhibitor or any HCV NS5A inhibitor\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ While on Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"HCV RNA Change From Baseline","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.23","spread":"0.592"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.79","spread":"0.627"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.10","spread":"0.546"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.11","spread":"0.552"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.11","spread":"0.554"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.11","spread":"0.554"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.11","spread":"0.556"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure","description":"Virologic failure was defined as:\n\n* On-treatment virologic failure:\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n  * Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n* Virologic relapse:\n\n  * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":111},"commonTop":["Headache","Fatigue","Nausea","Diarrhoea","Cough"]}}}